MedPath

Alvelestat

Generic Name
Alvelestat
Drug Type
Small Molecule
Chemical Formula
C25H22F3N5O4S
CAS Number
848141-11-7
Unique Ingredient Identifier
6Y5629322X
Background

Alvelestat has been investigated for the basic science of Chronic Obstructive Pulmonary Disease.

Clinical Trials
Related News

COVID-19 Study of Safety and Tolerability of Alvelestat

Phase 1
Completed
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2020-09-07
Last Posted Date
2023-01-19
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
15
Registration Number
NCT04539795
Locations
πŸ‡ΊπŸ‡Έ

UAB Lung Health Center, Birmingham, Alabama, United States

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1
Withdrawn
Conditions
Hematologic Malignancy
Interventions
Drug: Placebo
First Posted Date
2019-06-14
Last Posted Date
2020-03-20
Lead Sponsor
Nelson Chao
Registration Number
NCT03986086
Locations
πŸ‡ΊπŸ‡Έ

Duke University Adult Bone Marrow Transplant Clinic, Durham, North Carolina, United States

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Phase 2
Completed
Conditions
Alpha-1 Antitrypsin Deficiency (AATD)
Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations
Emphysema or COPD
Interventions
Other: Placebo
First Posted Date
2018-09-20
Last Posted Date
2024-08-20
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
63
Registration Number
NCT03679598
Locations
πŸ‡ΊπŸ‡Έ

Medical University of South Carolina, Charleston, South Carolina, United States

πŸ‡ΊπŸ‡Έ

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

πŸ‡ΊπŸ‡Έ

The University of Alabama at Birmingham Lung Health Center, Birmingham, Alabama, United States

and more 7 locations

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

Phase 2
Completed
Conditions
Emphysema
COPD
Alpha 1-Antitrypsin Deficiency
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2018-08-17
Last Posted Date
2022-04-14
Lead Sponsor
Mereo BioPharma
Target Recruit Count
99
Registration Number
NCT03636347
Locations
πŸ‡ΊπŸ‡Έ

UCLA Medical Center, Los Angeles, California, United States

πŸ‡©πŸ‡°

Aarhus Universitetshospital, Aarhus, Denmark

πŸ‡ΈπŸ‡ͺ

Lund University Hospital, Lund, Sweden

and more 23 locations

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1
Recruiting
Conditions
Chronic Graft vs Host Disease
Chronic Graft-Versus-Host Disease
Bronchiolitis Obliterans Syndrome
Interventions
First Posted Date
2016-02-01
Last Posted Date
2025-05-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
34
Registration Number
NCT02669251
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Phase 2
Completed
Conditions
Insulin Resistance
Type 2 Diabetes Mellitus
Interventions
Drug: placebo
First Posted Date
2015-11-05
Last Posted Date
2021-05-13
Lead Sponsor
Nick Giannoukakis, PhD
Target Recruit Count
14
Registration Number
NCT02597101
Locations
πŸ‡ΊπŸ‡Έ

Allegheny Health Network, Pittsburgh, Pennsylvania, United States

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

Phase 1
Withdrawn
Conditions
Pharmacokinetics
Pharmacodynamics
Interventions
First Posted Date
2010-10-04
Last Posted Date
2013-01-29
Lead Sponsor
AstraZeneca
Registration Number
NCT01214122
Locations
πŸ‡ΈπŸ‡ͺ

Research Site, Uppsala, Sweden

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-07-13
Last Posted Date
2011-02-09
Lead Sponsor
AstraZeneca
Target Recruit Count
6
Registration Number
NCT01161355
Locations
πŸ‡¬πŸ‡§

Research Site, London, United Kingdom

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Drug: Placebo
First Posted Date
2010-01-22
Last Posted Date
2012-08-20
Lead Sponsor
AstraZeneca
Target Recruit Count
52
Registration Number
NCT01054170
Locations
πŸ‡ΊπŸ‡¦

Research Site, Kyiv, Ukraine

AZD9668 Relative Bioavailability

Phase 1
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2009-12-18
Last Posted Date
2013-01-29
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT01035411
Locations
πŸ‡©πŸ‡ͺ

Research Site, Berlin, Germany

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy